»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ H(Z88.OM
xjVS
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 [Ki0b^
N9v1[~ bv_
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© lhBT@5Dm9
1.Antigen presenting cell£¨APC£© LRNh@g4ei
2.Activation induced cell death£¨AICD£© 6Q${U7%7
3.Chemokine IWY;="
4.Major histocompatibility complex£¨MHC£© <kx&w(=
5.immunotolerance E6pMT^{K
TL}++e
7+
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© %|^fi8!:|
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ orjj'+;X
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà !lj| cT9
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ ~,i-8jl,
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ \Ol kM<
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã :(M(>4t
pLLGus+W
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© ]3X@
_NYj
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ -(~!Jo_*'
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ -@0GcUE:r
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ U
G~b a
Z|l
qb=
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ d'G0m9u2
Y7*U:I+N
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 ):b$xNn
xUa{1!Y8
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ @Bf%s(Uj+
1.Antigenic determinant Q+W1lv8R
2.IgSF ZHm7Isa1
3.MBL;¾¶ T^Ze3L]
4.chemokine Lcg)UcB-#
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ &C"L
6.TCR-CD3¸´ºÏÎï ]]oI#*c
7.FADD£¨Fas-associated protein with death domain£© 2C9V|[U,
8.AIDS {;:/-0s
9.Tumor rejection antigen &8g?4
v
10.AICD +i@y@<l:+
[&#/]Ul'
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ woD>!r>)
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© DUC#NZgw
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ b-{=s+
:
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ h3z{(-~y
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì _YLfL
/Q2mMSK1h
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ q&W[j5E
k=4N.*#`y
oBzfbg8p
רҵ¿Î ÃâÒßѧ Pyb Z)5u
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê p%*%n3bw
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell S/ODqL|
5. Fc¦Å receptor 6. Cytokine .7.b:Dn0
¶þ¡¢ ÎÊ´ðÌâ b;cdIl!3
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 OG~6L4"
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ 3P^sM1
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ }5}.lJ:
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 7zSLAHW
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦Óᣠj+["JXy
Ct=-4
Ire\i7MF:
j{9D{
Y!gCMLL
^*S)t.
"
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ YJ;j x0
!>e5z|1
jlBanGs?
רҵ¿Î ÃâÒßѧ `9uB~LY^i
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê jp"JafS/E
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen 2GWMlI
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin %_{tzXim
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test sZL#xZ5
Df
9. Hybridoma technic 10.Mitogen _&j}<K$-(
11.Dentritic cell 12.Immunoproliferation Z6_N$Z.A
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ 1QU:?_\6@t
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ C_n9T{k
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦ÓᣠHKqwE=NZ
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ +AHUp)
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ B|4X}*@SX
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ PB/IFsJ
Bnb#{tL
t@R
?Rgu3
<YOLx R
&g.+V/<[
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 2Ri{bWi
i%g#+Gw
d8m6B6
CW
רҵ¿Î ÃâÒßѧ Q<KvBgmT
Ò»¡¢ Ãû´Ê½âÊÍ )E,\H@A
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï XvE9b5}
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà rN%F)
q#
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ >2Jdq
¶þ¡¢ ÎÊ´ðÌâ :^fcC[$K
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ >zhO7,=,
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£ C%U`"-%n@7
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£
k0
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ EloMe~a3
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ x#Q>J"g
lr{?"tl_
]miy/V }5
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ T<L^N+<,{N
m@Qt.4m%g
/MF!GM
רҵ¿Î ÃâÒßѧ vi|R(&
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê OZIW_'Wm/
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR ~j#]tElb
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA cI=r+OGk*
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM BA:yQ
¶þ¡¢ ÎÊ´ðÌâ #!$GH_
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£ PI~1GyJr@;
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ C-?%uF
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ S<L.c
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ h@@nR(<i
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ U|5nNiJM
PT^c^{V
[F*4EGB
xxm%u9@s
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ r&2~~_d3y
'Vr$MaO
qU,c~C=Qf
רҵ¿Î ÃâÒßѧ ,j?.4{rHJ
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê yCXrVN:`,
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule ~+H"
-+
5. Autogous mixed lymphoyte reaction ZZj~GQL(S
¶þ¡¢ ÎÊ´ðÌâ ~=wCwA|1
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ Pe_!?:vF
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ y?)}8T^
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷Óᣠ_oB_YL;,*
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿ zi'Jr)n
=X!IHd0
ZO7&vF}
6 8iV/7
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ]}mxY
vu_i
Q*YYTmZ
/_\#zC[
רҵ¿Î ÃâÒßѧ o]LRzI
45@]:2j
!$g+F(:(c
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê -z:&*=
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance }4>JO""
5. Delayed type hypersensitivity `aqrSH5^h
¶þ¡¢ ÎÊ´ðÌâ {S<>&?XB
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ w#
*1 /N
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ R
4wr
3. ¼òÊöHLAÓëҽѧµÄ¹ØÏµ¡£ *fO{ a
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷Óᣠl+y}4k=/
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷ÓᣠL fl-!1
zQH]s?v
(shK
"%@uO)A /
!7U\J]
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ vtMJ@!MN;
@("}]/O
V:
-qe bQv
רҵ¿Î ÃâÒßѧ z}.D"
P+
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê BN@,/m9OQ%
1. hypersensitivity 2. cluster of differentiation 6U,fz#<,}
3. adhesion molecules 4. supper antigen 5. split tolerance ^GYq#q9Q
¶þ¡¢ ÎÊ´ðÌâ nDlO5 pe"d
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ 3SARr>HRyI
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ 5@XV6
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ Cj&$%sO1
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£
'H FK Bp
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ [BBpQN.^q6
XLTD;[jO
0k?Sq#7q
98*x 'Wp
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ C=VIT*=
רҵ¿Î ÃâÒßѧ u fw cF*
Ò»¡¢ Ãû´Ê½âÊÍ 2z983^
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å aed+C:N
5. GVHR =ef1XQ{i*
¶þ¡¢ ÎÊ´ðÌâ m{&w{3pQk
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷Óᣠp(7QAd4
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌØµãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ (G8
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌØµã¡£ /R%^rz'w
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ *fP(6e#G,
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ \$;~74}
8X~h?^Vz
@\~tHJ?hQd
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ G&o64W;-s
~JE|f 7
'\L0xw4
רҵ¿Î ÃâÒßѧ ~Oh=
Ò»¡¢Ãû´Ê½âÊÍ l<2oklo5
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å gPUo25@pn*
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ G{A)H_o*
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ lf8xL9v
11. »ìºÏÁܰÍϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ ,xj3w#`zaf
Èý¡¢ ÎÊ´ðÌâ }Z-I2
=]
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ wA r~<
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ tzNaw %\
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà va>"#;37
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ ru(J5+H
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ M1(9A>|nF
K6(.KEW
6oA~J]<
bx7\QU+
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ A:c]1
GY7s
wlL8X7+:
רҵ¿Î ÃâÒßѧ QnP
{$rT
Ò»¡¢Ãû´Ê½âÊÍ u/#&0_
P
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó mw Z'=H
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁܰÍϸ°ûµÄ±íÃæ±êÖ¾ 0IpST
Èý¡¢ ÎÊ´ðÌâ +
lP5XY{
1. ¼òÊöTÁܰÍϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ `>\4"`I
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ @?Fx
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ ?n&$m
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ 1N>6rN
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ =tNzGaWJ
2mSD"[%
Gxo#
!
s><IykIi
Ou? r {$(b
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ [\88@B=jXP
Ò»¡¢Ãû´Ê½âÊÍ rQn{L{
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï G{/; AK
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó ,7t3>9-M"
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ =zz+<
!!
¶þ¡¢ ÎÊ´ðÌâ m';#R9\Fz
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ 8g.AT@ ,Q
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ =?wMESU
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ "
\`BPN
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ (rAiDRQ[
T=^jCH &
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ r>E\Cco
Ò»¡¢ Ãû´Ê½âÊÍ kV_#9z7%
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ FwXKRZa
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ 1% asx'^
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© YW'{|9KnI
10¡¢ ÒõÐÔÑ¡Ôñ ? 7/W>
¶þ¡¢ ÎÊ´ðÌâ R:]/{b4Uq
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 fS5GICx8R
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ >_&~!Y.Z=
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 tCuN?_UG
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ L[CU
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. :0WkxEY9
zv$Gma_
m$7x#8gF
: :F!
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ BPwI8\V
;3 G~["DA
44'=;/
רҵ¿Î ÃâÒßѧ xN e_qO
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ ;%BhhmR)[
1. Cytokines 2. adhesion molecules 3. graft versus host reaction >r;ABz/
4. immunologic tolerance 5. Opsonization %y~`"l$-
Èý¡¢ ÎÊ´ðÌâ &?KPu?9
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷ÓᣠfKPiRlLS
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ xP8iz?6"V
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ )9;
(>cdl
4. ÃâÒßϵͳɱÉ˰Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ HF*j`}
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ bHhC56[M
XD;15a
Aivu %}_|
@m+pr\h(
l@,); w=_P
) 1lJ<g#
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ 0MwG}|RC
=?meO0]y
9F2P(aS
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ `U{o:
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ NWo7wVwc/c
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê tb-OKZq
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ (P
E#
Y(
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û .jU|gf:x
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö 5;3c<
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð l%sp[uqcg
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖÆ±¸ÔÀí¡£ |1dEs,z\
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ 1R5\GKF6o
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃæ¿¹ÔºÍ±íÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© E3CiZ4=5
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ iF#}t(CrH
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ *_4n2<W$
()@.;R.Z
L|]w3}ZT@
H6%!v1 u
[a>JG8[,t
Y{Y;EY4
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ Z ]7;u>2
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ 3PvZ_
!G
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ :/yr(V{
t_dw}I
Ò»¡¢ Ãû´Ê½âÊÍ APHtJoS
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß X%4uShM
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò @n~>j&Kp
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô Z!]U&Ax`Z
¶þ¡¢ÎÊ´ðÌâ SCfkv|hO
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ #FQm/Q<0
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì 9Th32}H
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì N#pl mPrZ
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ A/$KA'jX
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ AjL?Qh4
sO{0hZkc